Briefing
ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial.
Baseline ctDNA was detectable in only 5.4% (16-plex) and 8.2% (64-plex) of 736 analyzed patients. ctDNA positivity was associated with worse DFS in both arms (P<0.05 for both assays), but sensitivity to predict DFS events was low and specificity was high. Among patients detectable at baseline and evaluable at cycle 5 day 1, clearance occurred in 6/10 vs 3/14 (16-plex) and 10/18 vs 9/25 (64-plex) with pembrolizumab vs placebo. The abstract concludes these data highlight limitations of these assays in clear-cell RCC.
- n: 994 randomized (496 pembrolizumab, 498 placebo); baseline ctDNA in 736; cycle 5 day 1 ctDNA in 641
- Assay: Natera Signatera RUO tissue-exome-based 16-plex and 64-plex assays